- Home
- ZH vs RCKT Comparison
ZH vs RCKT Comparison
Compare ZH & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- RCKT
- Stock Information
- Founded
- ZH 2011
- RCKT 1999
- Country
- ZH China
- RCKT United States
- Employees
- ZH N/A
- RCKT N/A
- Industry
- ZH Business Services
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- RCKT Health Care
- Exchange
- ZH Nasdaq
- RCKT Nasdaq
- Market Cap
- ZH 365.1M
- RCKT 328.6M
- IPO Year
- ZH 2021
- RCKT N/A
- Fundamental
- Price
- ZH $4.81
- RCKT $3.28
- Analyst Decision
- ZH Strong Buy
- RCKT Buy
- Analyst Count
- ZH 1
- RCKT 13
- Target Price
- ZH $4.70
- RCKT $12.96
- AVG Volume (30 Days)
- ZH 390.5K
- RCKT 6.0M
- Earning Date
- ZH 08-27-2025
- RCKT 08-07-2025
- Dividend Yield
- ZH N/A
- RCKT N/A
- EPS Growth
- ZH N/A
- RCKT N/A
- EPS
- ZH 0.22
- RCKT N/A
- Revenue
- ZH $439,821,184.00
- RCKT N/A
- Revenue This Year
- ZH N/A
- RCKT N/A
- Revenue Next Year
- ZH $7.46
- RCKT $108.43
- P/E Ratio
- ZH $21.62
- RCKT N/A
- Revenue Growth
- ZH N/A
- RCKT N/A
- 52 Week Low
- ZH $3.13
- RCKT $2.19
- 52 Week High
- ZH $6.32
- RCKT $22.01
- Technical
- Relative Strength Index (RSI)
- ZH 56.37
- RCKT 51.17
- Support Level
- ZH $4.58
- RCKT $2.88
- Resistance Level
- ZH $5.01
- RCKT $3.74
- Average True Range (ATR)
- ZH 0.28
- RCKT 0.27
- MACD
- ZH 0.02
- RCKT 0.02
- Stochastic Oscillator
- ZH 55.91
- RCKT 35.43
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.